Four partners have gotten together in the hopes of developing technology to replace traditional glucometers--and maybe even manage insulin delivery with smartphone-based systems. Wearables specialist Gentag and the Mayo Clinic are expanding upon their ongoing collaboration and adding into the mix a pair of existing partners: sensor maker NovioSense and the Fraunhofer Institute for Microelectronic Circuits and Systems (IMS).
Valeant Pharmaceuticals will commercialize and manufacture a delivery system and reformulated, topically active corticosteroid to treat uveitis developed EyeGate.
The year's 10 highest-paid development executives pulled in $124.4 million in total compensation, a roughly 35% jump over 2013's top earners. And while each entrant benefited from meeting individual company goals, the whole group benefited from biopharma's macroeconomic moment in the sun, as the value of stock awards skyrocketed alongside the industry index.
GlaxoSmithKline is the first pharma company to get behind the U.K.'s forthcoming Francis Crick Institute, signing on to lend its minds and molecules to an open R&D effort.
Now that billionaire entrepreneur Patrick Soon-Shiong has taken control of tiny ConkWest and steered it toward a $173 million IPO, he's adding a makeover to the name that will fit more easily under the fast-growing NantWorks umbrella he's created.
Moving on from a painful Phase II failure for its top prospect, Ohr Pharmaceutical heralded new hope for the eye drop in retinal vein occlusion thanks to some positive results from a midstage study.
Otsuka and its partner Lundbeck snagged an FDA approval for Rexulti (brexpiprazole) to treat schizophrenia and as an add-on therapy for major depression, leaving the two companies prepping for an August launch into an increasingly crowded field.
ResearchKit, the technology Apple promises will transform the world's hundreds of millions of iPhones into handheld gatherers of clinical data, could become a viable tool in drug development, and two major drugmakers are working to integrated into clinical trials.
Catheters designed to deliver chemotherapy are often coated in silver to provide an antibacterial coating. But scientists at the Norwegian University of Science and Technology found that this silver actually breaks down chemotherapy drugs and can release a harmful gas, hydrogen fluoride in the process.
The rapid maturation of gene therapy technologies has galvanized a wide range of projects throughout industry and academia, and now a team of researchers from Harvard and Boston Children's Hospital believe they may have come up with a one-time treatment for a genetic cause of deafness.